Sun Yue-Meng, Wang Zhi-Yun, Liang Yuan-Yuan, Hao Chen-Wei, Shi Chang-He
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
Henan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
NPJ Digit Med. 2024 Aug 21;7(1):218. doi: 10.1038/s41746-024-01217-2.
Parkinson's disease (PD) is a multifactorial neurodegenerative disorder with high prevalence among the elderly, primarily manifested by progressive decline in motor function. The aging global demographic and increased life expectancy have led to a rapid surge in PD cases, imposing a significant societal burden. PD along with other neurodegenerative diseases has garnered increasing attention from the scientific community. In PD, motor symptoms are recognized when approximately 60% of dopaminergic neurons have been damaged. The irreversible feature of PD and benefits of early intervention underscore the importance of disease onset prediction and prompt diagnosis. The advent of digital health technology in recent years has elevated the role of digital biomarkers in precisely and sensitively detecting early PD clinical symptoms, evaluating treatment effectiveness, and guiding clinical medication, focusing especially on motor function, responsiveness and sleep quality assessments. This review examines prevalent digital biomarkers for PD and highlights the latest advancements.
帕金森病(PD)是一种多因素神经退行性疾病,在老年人中患病率较高,主要表现为运动功能进行性下降。全球人口老龄化和预期寿命的增加导致帕金森病病例迅速激增,给社会带来了沉重负担。帕金森病以及其他神经退行性疾病已引起科学界越来越多的关注。在帕金森病中,当约60%的多巴胺能神经元受损时,运动症状才会被识别出来。帕金森病的不可逆特征以及早期干预的益处凸显了疾病发病预测和及时诊断的重要性。近年来数字健康技术的出现提升了数字生物标志物在精确、灵敏地检测帕金森病早期临床症状、评估治疗效果和指导临床用药方面的作用,尤其侧重于运动功能、反应性和睡眠质量评估。本综述探讨了帕金森病常见的数字生物标志物,并突出了最新进展。